Background: MicroRNAs (miRNAs) are small non‐coding RNAs with regulatory functions as tumour suppressors and oncogenes. Although single nucleotide polymorphism (SNP) in miRNA regions have been reported to be rare and unlikely to be functionally important, recent evidence suggested that rs11614913 SNP in miR‐196a2 was associated with the susceptibility of lung cancer, breast cancer, congenital heart disease and shortened survival time of non‐small‐cell lung cancer. Aims: The aim of this study was to investigate the association between this genetic variant and the risk and/or progression of colorectal cancer (CRC). Methods: A total of 126 CRC patients and 407 healthy controls was periodically enrolled. DNA was extracted from blood specimens, and miR‐196a2 polymorphism was genotyped by polymerase chain reaction–ligation detection reaction (PCR–LDR). Results: Although the frequency of CC homozygotes or miR‐196a2C allele‐containing genotypes (CT and CC) was lower in CRC patients than in the healthy controls, no significant association between miR‐196a2 polymorphism and the risk of CRC was found. The frequency of the ‘C’ allele in CRC patients was also not significantly lower than in healthy controls. In a subsequent analysis of the association between this polymorphism and the progression of CRC, there was still no significant difference in both genotype and allelic frequency. Conclusions: Our results suggest that miR‐196a2 polymorphism is not associated with both an increased risk and progression of CRC in Chinese. 相似文献
Introduction: Epigenetics is a rapidly growing field describing heritable alterations in gene expression that do not involve DNA sequence variations. Advances in epigenetics and epigenomics have influenced pharmacology, leading to the development of a new specialty, pharmacoepigenetics, the study of the epigenetic basis for the individual variation in drug response.
Areas covered: We present an overview of the major epigenetic mechanisms and their effects on the expression of drug metabolizing enzymes and drug transporters, as well as the epigenetic status of drug protein targets affecting therapy response. Recent advances in the development of pharmacoepigenetic biomarkers and epidrugs are also discussed.
Expert opinion: There is growing evidence that pharmacoepigenetics has the potential to become an important element of personalized medicine. Epigenetic modifications influence drug response, but they can also be modulated by drugs. Moreover, they can be monitored not only in the affected tissue, but also in body fluids. Nevertheless, there are very few examples of epigenetic biomarkers implemented in the clinical setting. Explanation of the interplay between genomic and epigenomic changes will contribute to the personalized medicine approach. Ultimately, both genetic biomarkers and epigenetic mechanisms should be taken into consideration in predicting drug response in the course of successful personalized therapy. 相似文献
Objective miR-663 a has been reported to be downregulated by X-ray irradiation and participates in radiation-induced bystander effect via TGF-β1. The goal of this study was to explore the role of mi R-663 a during radiation-induced Epithelium-to-mesenchymal transition(EMT).Methods TGF-β1 or IR was used to induce EMT. After mi R-663 a transfection, cell migration and cell morphological changes were detected and the expression levels of mi R-663 a, TGF-β1, and EMT-related factors were quantified.R... 相似文献